Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

EYE 201

Next Previous
Drug Profile

EYE 201

Alternative Names: EYE-201; MK-8748; Tiespectus - Merck

Latest Information Update: 08 Sep 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator EyeBio
  • Developer EyeBio; Merck AG
  • Class Bispecific antibodies; Eye disorder therapies; Recombinant fusion proteins
  • Mechanism of Action TIE-2 receptor agonists; Vascular endothelial growth factor A inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Diabetic macular oedema
  • Phase II/III Age-related macular degeneration; Choroidal neovascularisation; Wet age-related macular degeneration
  • Phase I/II Retinal vein occlusion

Most Recent Events

  • 27 Aug 2026 Phase-III clinical trials in Diabetic macular oedema in USA (Intravitreous) (NCT07705555)
  • 11 Aug 2026 EyeBio completes the phase I/IIa RIOJA trial in Diabetic macular edema, Age-related macular degeneration and Retinal vein occlusion in USA and Puerto Rico (Intravitreous, Solution) (NCT06664502)
  • 15 Jul 2026 Merck Sharp & Dohme plans a phase III trial for Diabetic macular oedema (Treatment-naive, Treatment experienced) (Intravitreous) in August 2026 (NCT07705555)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top